Rodondi Nicolas, Bauer Douglas C, Cappola Anne R, Cornuz Jacques, Robbins John, Fried Linda P, Ladenson Paul W, Vittinghoff Eric, Gottdiener John S, Newman Anne B
Department of Ambulatory Care and Community Medicine, University of Lausanne, Lausanne, Switzerland.
J Am Coll Cardiol. 2008 Sep 30;52(14):1152-9. doi: 10.1016/j.jacc.2008.07.009.
The goal of this study was to determine whether subclinical thyroid dysfunction was associated with incident heart failure (HF) and echocardiogram abnormalities.
Subclinical hypothyroidism and hyperthyroidism have been associated with cardiac dysfunction. However, long-term data on the risk of HF are limited.
We studied 3,044 adults>or=65 years of age who initially were free of HF in the Cardiovascular Health Study. We compared adjudicated HF events over a mean 12-year follow-up and changes in cardiac function over the course of 5 years among euthyroid participants, those with subclinical hypothyroidism (subdivided by thyroid-stimulating hormone [TSH] levels: 4.5 to 9.9, >or=10.0 mU/l), and those with subclinical hyperthyroidism.
Over the course of 12 years, 736 participants developed HF events. Participants with TSH>or=10.0 mU/l had a greater incidence of HF compared with euthyroid participants (41.7 vs. 22.9 per 1,000 person years, p=0.01; adjusted hazard ratio: 1.88; 95% confidence interval: 1.05 to 3.34). Baseline peak E velocity, which is an echocardiographic measurement of diastolic function associated with incident HF in the CHS cohort, was greater in those patients with TSH>or=10.0 mU/l compared with euthyroid participants (0.80 m/s vs. 0.72 m/s, p=0.002). Over the course of 5 years, left ventricular mass increased among those with TSH>or=10.0 mU/l, but other echocardiographic measurements were unchanged. Those patients with TSH 4.5 to 9.9 mU/l or with subclinical hyperthyroidism had no increase in risk of HF.
Compared with euthyroid older adults, those adults with TSH>or=10.0 mU/l have a moderately increased risk of HF and alterations in cardiac function but not older adults with TSH<10.0 mU/l. Clinical trials should assess whether the risk of HF might be ameliorated by thyroxine replacement in individuals with TSH>or=10.0 mU/l.
本研究的目的是确定亚临床甲状腺功能障碍是否与新发心力衰竭(HF)及超声心动图异常相关。
亚临床甲状腺功能减退和甲状腺功能亢进与心脏功能障碍有关。然而,关于HF风险的长期数据有限。
我们在心血管健康研究中对3044名年龄≥65岁且最初无HF的成年人进行了研究。我们比较了甲状腺功能正常参与者、亚临床甲状腺功能减退参与者(根据促甲状腺激素[TSH]水平细分:4.5至9.9、≥10.0 mU/l)和亚临床甲状腺功能亢进参与者在平均12年随访期间判定的HF事件以及5年内心脏功能的变化。
在12年期间,736名参与者发生了HF事件。TSH≥10.0 mU/l的参与者与甲状腺功能正常的参与者相比,HF发病率更高(每1000人年41.7例对22.9例,p = 0.01;调整后的风险比:1.88;95%置信区间:1.05至3.34)。在CHS队列中,基线E峰速度是与新发HF相关的舒张功能的超声心动图测量指标,TSH≥10.0 mU/l的患者与甲状腺功能正常的参与者相比更高(0.80 m/s对0.72 m/s,p = 0.002)。在5年期间,TSH≥10.0 mU/l的参与者左心室质量增加,但其他超声心动图测量指标未改变。TSH为4.5至9.9 mU/l的患者或亚临床甲状腺功能亢进患者的HF风险没有增加。
与甲状腺功能正常的老年人相比,TSH≥10.0 mU/l的成年人HF风险适度增加且心脏功能有改变,但TSH<10.0 mU/l的成年人则不然。临床试验应评估TSH≥10.0 mU/l的个体进行甲状腺素替代治疗是否可改善HF风险。